• Legend Biotech recently reported early Phase 1 data for LB2501, an investigational in vivo CD19/CD20 dual-targeting CAR-T therapy, showing a 100% objective response rate and 83.3% complete response rate at the higher dose in relapsed/refractory B-cell non-Hodgkin lymphoma, with no serious adverse events and durable in vivo CAR-T cell expansion without lymphodepleting chemotherapy.
• The ability of LB2501 to generate CAR-T cells directly inside patients from a single off-the-shelf infusion could materially reduce manufacturing complexity and treatment bottlenecks that have historically limited access to CAR-T therapies.
• We’ll now examine how this early, off-the-shelf in vivo CAR-T success might influence Legend Biotech’s multiple myeloma-focused investment narrative.

The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 13 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

Legend Biotech Investment Narrative Recap

To own Legend Biotech today, you have to believe CARVYKTI can keep driving revenue while the pipeline adds new growth legs before costs overwhelm the story. The LB2501 in vivo CAR-T data strengthens Legend’s case that it can participate in the shift toward off the shelf cell therapies, but the most important near term catalyst and biggest risk still sit with CARVYKTI’s commercial and safety profile rather than this very early lymphoma readout.

The announcement that more than 10,000 patients have now been treated with CARVYKTI, backed by updated CARTITUDE data showing consistent benefit across risk groups, is the most relevant context for LB2501. Together, they highlight how Legend is trying to balance a still concentrated, autologous MM franchise with a next generation platform that could change how CAR-T is delivered if later stage data hold up.

Yet despite the excitement around CARVYKTI’s growth and LB2501’s early data, investors should be aware that a key risk remains that ...

Legend Biotech's narrative projects $2.1 billion revenue and $501.1 million earnings by 2029.

Uncover how Legend Biotech's forecasts yield a $57.24 fair value, a 58% upside to its current price.

Exploring Other Perspectives

While consensus keeps expectations more measured, some of the most optimistic analysts were already modeling US$2.7 billion in 2029 revenue and US$869.2 million in earnings before this LB2501 update, which shows how differently you and other shareholders might weigh pipeline potential against the risk that heavy reliance on CARVYKTI could still backfire.

Explore 5 other fair value estimates on Legend Biotech - why the stock might be worth over 3x more than the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Legend Biotech research is our analysis highlighting 1 key reward and 1 important warning sign that could impact your investment decision.
• Our free Legend Biotech research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Legend Biotech's overall financial health at a glance.

Looking For Alternative Opportunities?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.
• AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Uncover the next big thing with 24 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.